A Phase II study showed that Cell>Point's SPECT imaging agent, technetium-99m ethylene dicysteine deoxyglucose, is comparable to FDG-PET in zeroing in on primary and metastatic lesions. The study also showed that ECDG-SPECT could pick up tumors located in the marrow of long bones, which could not be viewed with FDG-PET. The company is now planning to move on to Phase III trials.
A guidance released by CMS aims to assist state Medicaid agencies with implementing incentive programs for the meaningful use of electronic health records as well as outline the criteria for receiving the 90% federal financing for administrative expenses. "CMS expects that states will take an incremental approach to the initial implementation of their Medicaid EHR Incentive Programs," the agency said.
The FDA has given 510(k) clearance to Digirad to market its Cardius X-ACT imaging system. The cardiac SPECT/CT device is capable of low-dose VCT attenuation correction to limit image artifacts caused by overlying tissues. It features a 24-inch-wide detector array and triple-head solid-state digital detectors.